AMEX · IBO
Impact BioMedical Inc.
$3.99+$0.00 (0.0%)
Impact BioMedical Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.02% below the high.
Loading market information…
NASDAQ · CDIO · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Cardio Diagnostics Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 77.88% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Cardio Diagnostics Holdings, Inc.’s next earnings report is currently expected on Nov 6, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Cardio Diagnostics Holdings, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Cardio Diagnostics Holdings, Inc. specializes in creating and bringing to market advanced clinical diagnostic tools that leverage epigenetic insights to address cardiovascular disease. Among their key offerings is Epi+Gen CHD, a test designed to assess an individual's three-year risk for developing symptomatic coronary heart disease. This company, headquartered in Chicago, Illinois, was established in 2017.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | Apr 1, 2025 | -$0.06+62.5% vs estimate | $25.00K0.0% vs estimate |
|---|
| Q3 2024 | Nov 13, 2024 | -$1.73-1,053.33% vs estimate | $6.58K-6.0% vs estimate |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.99+$0.00 (0.0%)
Impact BioMedical Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.02% below the high.
$0.93-$0.02 (-2.26%)
BioCardia, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.56% below the high.
$5.05+$1.34 (+36.12%)
Adial Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 45.41% below the high.
$0.91+$0.11 (+13.78%)
Brainstorm Cell Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.15% below the high.
$1.89-$0.24 (-11.27%)
Alaunos Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.0% below the high.
$2.13-$0.23 (-9.75%)
NeuroSense Therapeutics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 91.61% below the high.
$2.93-$0.03 (-1.01%)
Addex Therapeutics Ltd’s quoted price sits in the lower half of its reported 52-week range, 71.91% below the high.
$0.68-$0.04 (-5.78%)
Creative Medical Technology Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 85.63% below the high.
